Open-label study of COMP360 psilocybin therapy for

https://www.globenewswire.com/news-release/2021/10/20/2317456/0/en/Open-label-study-of-COMP360-psilocybin-therapy-for-depression-in-cancer-patients-demonstrates-feasibility-of-simultaneous-psilocybin-administration-in-small-groups.html

Professor Guy Goodwin, Chief Medical Officer, COMPASS Pathways, said: “These preliminary findings suggest COMP360 psilocybin therapy was well tolerated by cancer patients with major depressive disorder. It is promising to see that this may be a feasible fast-acting therapy for depressed patients with a significant physical co-morbidity. This would certainly be welcome in conditions where depression is difficult to treat in a timely way.”

These results are exciting especially when you’ve been told that you have treatment-resistant depression.

What I can say as a practicing Psychedelic Integration Therapist is that I have personally witnessed clients face, engage and participate in their lives more after consuming a microdose of psilocybin. Tracking the subtle shift in light, breath, and body sensations offers self agency. And when clients regulate their own regimen of amount and frequency of microdosing psychedelics, they are in the driver’s seat of their self-discovery.

Imagine that 1/10 of a gram of magic mushrooms ground up in a powder, literally a pinch!, when consumed can offer the slightest shift of perspective. Instead of drugging themselves, they consume a supplement. The mindset of self discovery rather than treatment sheds light on the resilience and vitality of the individual. Within the psychedelic context we expand the definition of wholeness and what is within our reach. Spirituality and Science intersect and then the human condition can be perceived with reverence and awe.

Leave a Reply